Boule Diagnostics AB - Asset Resilience Ratio

Latest as of June 2025: 4.94%

Boule Diagnostics AB (BOUL) has an Asset Resilience Ratio of 4.94% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Boule Diagnostics AB (BOUL) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr23.00 Million
≈ $2.48 Million USD Cash + Short-term Investments

Total Assets

Skr465.40 Million
≈ $50.08 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Boule Diagnostics AB's Asset Resilience Ratio has changed over time. See BOUL total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Boule Diagnostics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Boule Diagnostics AB (BOUL) market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr23.00 Million 4.94%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr23.00 Million 4.94%

Asset Resilience Insights

  • Limited Liquidity: Boule Diagnostics AB maintains only 4.94% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Boule Diagnostics AB Industry Peers by Asset Resilience Ratio

Compare Boule Diagnostics AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Double Medical Technology Inc
SHE:002901
Medical Devices 7.79%
Beijing Wandong Medical Technology Co Ltd
SHG:600055
Medical Devices 4.92%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
MODULIGHT OY EO 1
F:78W
Medical Devices 22.31%
Diagnostic Medical Systems SA
PA:ALDMS
Medical Devices 1.39%
Theradiag SA
PA:ALTHE
Medical Devices 15.59%
Nova EYE Medical Ltd
AU:EYE
Medical Devices 11.08%

Annual Asset Resilience Ratio for Boule Diagnostics AB (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Boule Diagnostics AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 4.48% Skr26.43 Million
≈ $2.84 Million
Skr590.20 Million
≈ $63.51 Million
-0.45pp
2023-12-31 4.93% Skr37.23 Million
≈ $4.01 Million
Skr755.11 Million
≈ $81.26 Million
-1.80pp
2022-12-31 6.73% Skr51.11 Million
≈ $5.50 Million
Skr759.96 Million
≈ $81.78 Million
+6.49pp
2021-12-31 0.24% Skr1.36 Million
≈ $146.36K
Skr572.03 Million
≈ $61.56 Million
+1.04pp
2020-12-31 -0.80% Skr-3.83 Million
≈ $-411.85K
Skr479.71 Million
≈ $51.62 Million
+3.58pp
2019-12-31 -4.38% Skr-25.70 Million
≈ $-2.77 Million
Skr586.87 Million
≈ $63.16 Million
-2.21pp
2018-12-31 -2.17% Skr-10.86 Million
≈ $-1.17 Million
Skr500.85 Million
≈ $53.90 Million
-25.98pp
2017-12-31 23.81% Skr99.16 Million
≈ $10.67 Million
Skr416.49 Million
≈ $44.82 Million
+11.57pp
2016-12-31 12.24% Skr44.59 Million
≈ $4.80 Million
Skr364.33 Million
≈ $39.21 Million
-30.74pp
2010-12-31 42.98% Skr88.58 Million
≈ $9.53 Million
Skr206.11 Million
≈ $22.18 Million
--
pp = percentage points

About Boule Diagnostics AB

ST:BOUL Sweden Medical Devices
Market Cap
$14.38 Million
Skr133.59 Million SEK
Market Cap Rank
#25961 Global
#545 in Sweden
Share Price
Skr3.44
Change (1 day)
-4.71%
52-Week Range
Skr3.44 - Skr10.30
All Time High
Skr74.05
About

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clini… Read more